News & Updates

Enzalutamide tied to better outcomes than bicalutamide in mHSPC

09 Apr 2021 by

A regimen comprising enzalutamide and androgen deprivation therapy (ADT) led to better outcomes compared with a bicalutamide-ADT regimen in an earlier setting of metastatic hormone-sensitive prostate cancer (mHSPC), particularly in Black men, a phase II study suggests.

Enzalutamide tied to better outcomes than bicalutamide in mHSPC

09 Apr 2021

5-alpha-reductase inhibitors beneficial to men with prostate cancer

09 Apr 2021

Men with prostate cancer on active surveillance appear to fare well with 5-alpha-reductase inhibitors, which can help reduce both grade and volume progression without increasing the risk of developing high-grade tumours, a study has found.

5-alpha-reductase inhibitors beneficial to men with prostate cancer

09 Apr 2021

Gemcitabine plus pazopanib improves PFS in advanced soft tissue sarcoma

09 Apr 2021 by

Adding gemcitabine to pazopanib led to a significantly higher progression-free survival (PFS) rate in patients with advanced soft tissue sarcoma compared with pazopanib alone, according to the PAPAGEMO* trial.

Gemcitabine plus pazopanib improves PFS in advanced soft tissue sarcoma

09 Apr 2021

Early-phase trial evidence for RRMM treatment highly heterogenous

08 Apr 2021

While early-phase clinical trials may demonstrate substantial levels of overall response rates in patients with relapsed/refractory multiple myeloma (RRMM), high heterogeneity of evidence prevents the accurate assessment of clinical benefit before patient participation, reports a recent meta-analysis.

Early-phase trial evidence for RRMM treatment highly heterogenous

08 Apr 2021

5 patterns of SARS-CoV-2 neutralizing antibody dynamics: What they mean

08 Apr 2021 by

Neutralizing antibody response against SARS-CoV-2 can be categorized into five patterns of response, with persistent neutralizing antibodies being correlated with severe COVID-19 disease and higher pro-inflammatory cytokine levels, according to a Singapore study.

5 patterns of SARS-CoV-2 neutralizing antibody dynamics: What they mean

08 Apr 2021

Pitolisant: New weapon in the battle to stay awake among CPAP-adherent OSA patients

08 Apr 2021 by

The selective histamine H3-receptor antagonist pitolisant appears to quell excessive daytime sleepiness in obstructive sleep apnoea (OSA) patients adherent to continuous positive airway pressure (CPAP) therapy, as shown in a phase III HAROSA I trial.

Pitolisant: New weapon in the battle to stay awake among CPAP-adherent OSA patients

08 Apr 2021

Prolonged opioid exposure can mess up cognition in seniors

08 Apr 2021

Persistent use of opioids for pain management in older adults may adversely affect their cognitive function, a study has found.

Prolonged opioid exposure can mess up cognition in seniors

08 Apr 2021

Fertility treatment bears no excess breast cancer risk for BRCA1/2 mutation carriers

08 Apr 2021

Among women carrying BRCA1/2 mutation, the use of fertility treatment does not contribute to a discernible increase in breast cancer risk, according to a study.

Fertility treatment bears no excess breast cancer risk for BRCA1/2 mutation carriers

08 Apr 2021

ACEi, ARB use not tied to increased COVID-19 diagnosis, complication risk

07 Apr 2021 by

Exposure to angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) does not appear to increase the risk of being diagnosed with COVID-19 or hospitalization for COVID-19–related outcomes, according to a study.

ACEi, ARB use not tied to increased COVID-19 diagnosis, complication risk

07 Apr 2021

Biologic works against axial psoriatic arthritis

07 Apr 2021 by

Secukinumab, at both 300 and 150 mg, scores high in the management of psoriatic arthritis (PsA) patients with axial manifestations and inadequate response to nonsteroidal anti-inflammatory drugs (NSAIDs), as shown in the results of the phase III MAXIMISE trial.

Biologic works against axial psoriatic arthritis

07 Apr 2021

News & Updates

Filter by Specialty:

Specialty:

Enzalutamide tied to better outcomes than bicalutamide in mHSPC

Enzalutamide tied to better outcomes than bicalutamide in mHSPC

5-alpha-reductase inhibitors beneficial to men with prostate cancer

5-alpha-reductase inhibitors beneficial to men with prostate cancer

Gemcitabine plus pazopanib improves PFS in advanced soft tissue sarcoma

Gemcitabine plus pazopanib improves PFS in advanced soft tissue sarcoma

Early-phase trial evidence for RRMM treatment highly heterogenous

Early-phase trial evidence for RRMM treatment highly heterogenous

5 patterns of SARS-CoV-2 neutralizing antibody dynamics: What they mean

5 patterns of SARS-CoV-2 neutralizing antibody dynamics: What they mean

Pitolisant: New weapon in the battle to stay awake among CPAP-adherent OSA patients

Pitolisant: New weapon in the battle to stay awake among CPAP-adherent OSA patients

Prolonged opioid exposure can mess up cognition in seniors

Prolonged opioid exposure can mess up cognition in seniors

Fertility treatment bears no excess breast cancer risk for BRCA1/2 mutation carriers

Fertility treatment bears no excess breast cancer risk for BRCA1/2 mutation carriers

ACEi, ARB use not tied to increased COVID-19 diagnosis, complication risk

ACEi, ARB use not tied to increased COVID-19 diagnosis, complication risk

Biologic works against axial psoriatic arthritis

Biologic works against axial psoriatic arthritis